Sofinnova Partners Raises €106 Million in a First Closing of Its Industrial Biotech Fund
Sofinnova Partners, a leading European venture capital firm specialized in life sciences, today announced the first closing of Sofinnova Industrial Biotech I (Sofinnova IB I) at €106 million. The fund, dedicated to renewable chemistry, follows a series of 9 investments in the sector since 2009, and places Sofinnova Partners at the forefront of this promising emerging market.
Sofinnova IB I will be invested in start-ups along the value chain from the transformation of renewable raw materials, like agricultural waste or C02 , to renewable end-products such as bio-plastics and other bio-sourced materials. It will equally look at technologies coming from advances in synthetic biology and alike. The investment thesis is based on growing market demand for innovative, renewable products leveraging non-fossil raw materials and novel technologies to produce better performing or cheaper, sustainable alternatives.
Pursuing the strategy applied consistently over the years with previous funds, Sofinnova Partners will seek to invest Sofinnova IB I as a founding and lead investor in start-ups and corporate spin-offs, in Europe and North America. The focus of the fund will consist in backing visionary entrepreneurs aiming at developing paradigm changing innovations from lab to the end users market. Sofinnova IB I will seek to invest in 8 to 10 companies during the next 3 to 4 years. It will leverage an experienced and dedicated team, initially composed of Denis Lucquin, Managing Partner, Joško Bobanović, Partner, and Michael Krel, Principal.
For this substantial first closing, Sofinnova IB I attracted premier investors, predominantly European institutions and major international industrial players, from energy, chemical and agricultural sectors, including several returning investors from the seed fund raised in 2012 in the same sector: Sofinnova Green Seed Fund.
Denis Lucquin, Managing Partner at Sofinnova Partners, said, “We are very pleased with the success of this first closing. The experience accumulated since 2009 resonated well with the investors. With investments in the sector ranging from Avantium, developing an entirely bio-based plastic bottle and now planning an IPO on Euronext, to the most recent DNA Script, revolutionizing DNA synthesis, Sofinnova Partners stands as a pioneer investor, benefitting from an acute understanding of the dynamics at work in this emerging sector. With establishment of this entirely dedicated fund, we have reached today a further important step in our development in industrial biotech.”
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together 12 highly experienced investment professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a founding and lead investor in start-ups and corporate spin-offs, and has backed nearly 500 companies over more than 40 years, creating market leaders around the globe. Today, Sofinnova Partners has over €1.6 billion under management.
For more information, please visit: www.sofinnova.fr
Anne REIN, Tel: +33 6 03 35 92 05
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
FOCP19.11.2017 17:33 | pressemeddelelse
Cancer Patients, Survivors, Supporters and Caregivers Undertake UAE's First Relay for Life
ASTRAZENECA19.11.2017 00:02 | pressemeddelelse
New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases
ASTRAZENECA18.11.2017 19:22 | pressemeddelelse
New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer
CHINA-HI-TECH-FAIR18.11.2017 10:13 | pressemeddelelse
Much-Anticipated CHTF 2017 Top 10 Products Are Unveiled
NY-MADISON-REALTY17.11.2017 17:22 | pressemeddelelse
Madison Realty Capital Provides $64.0 Million Construction Financing for 200 Kent Avenue Development in Williamsburg, Brooklyn
NCARDIA17.11.2017 13:33 | pressemeddelelse
Ncardia Announces Completion of €10.5M Investment Round
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum